NCT07705139 The Value of Bowel Sounds in Evaluating Postoperative Intestinal Function Recovery in Colorectal Cancer Patients
| NCT ID | NCT07705139 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhongnan Hospital |
| Condition | Bowel Sounds |
| Study Type | OBSERVATIONAL |
| Enrollment | 172 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2026-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 172 participants in total. It began in 2026-02-01 with a primary completion date of 2026-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study enrolls patients scheduled to undergo curative surgery for colorectal cancer. Bowel sounds will be assessed preoperatively and postoperatively. By comparing intraoperative variables, the incidence of perioperative complications, reoperation rates, and postoperative outcomes-including time to first flatus, resumption of oral intake, and occurrence of intestinal obstruction-this study aims to investigate the association between perioperative bowel sounds and postoperative recovery, and provide evidence-based support for the clinical application of bowel sound monitoring. Supplementary Definitions
Eligibility Criteria
Inclusion Criteria: * Aged 18-80 years. * Histopathologically confirmed colorectal adenocarcinoma according to the WHO 2022 classification. * No restriction on prior neoadjuvant or other antitumor therapies, including chemotherapy, radiotherapy, targeted therapy, or immunotherapy. * Able to understand the study requirements and voluntarily provide written informed consent (patient and/or legally authorized representative). * Able to communicate effectively with the investigators and willing to comply with all study procedures, including postoperative management and follow-up. Exclusion Criteria: * Significant organ dysfunction indicating inability to tolerate surgery or an unacceptably high perioperative risk, including: * Severe cardiac dysfunction (NYHA Class III or IV). * Severe hepatic dysfunction (MELD score \>12). * Severe renal dysfunction (eGFR \<30 mL/min/1.73 m² \[CKD stage 4-5\] or end-stage renal disease requiring dialysis). * Severe pulmonary dysfunction (resting PaO₂ \<60 mmHg on room air or respiratory failure requiring long-term oxygen therapy or mechanical ventilation). * Participation in another clinical study within 4 weeks before enrollment or concurrent participation in another interventional clinical study. * Emergency surgery required because of intestinal obstruction, perforation, or other acute abdominal conditions. * Severe psychiatric disorders that would interfere with compliance with perioperative management or follow-up. * Pregnant or breastfeeding women. * Any other clinical or laboratory abnormality that, in the opinion of the investigator, would make the participant unsuitable for the study.
Contact & Investigator
Congqing Jiang, professor
STUDY CHAIR
Shanghai Zhongshan Hospital
Frequently Asked Questions
Who can join the NCT07705139 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Bowel Sounds. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07705139 currently recruiting?
Yes, NCT07705139 is actively recruiting participants. Contact the research team at 2023283030136@whu.edu.cn for enrollment information.
Where is the NCT07705139 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT07705139 clinical trial?
NCT07705139 is sponsored by Zhongnan Hospital. The principal investigator is Congqing Jiang, professor at Shanghai Zhongshan Hospital. The trial plans to enroll 172 participants.